Around the nation: New York attorney general launches investigation into Mylan
Bite-sized hospital and health industry news
- Kansas: Mercy Hospital in Independence, Kansas, closed down in fall 2015, and many residents of the small town believe that city and state officials should have done more to save the hospital, Jim McLean reports for the Salina Post. Some believe that Kansas' decision not to expand Medicaid under the Affordable Care Act contributed to the hospital's closure—and that's prompted a few politicians to change their stances on Medicaid expansion. State House candidate Doug Blex (R) said, "Quite frankly, before the shock of the hospital (closure) hit me, I was leaning against it," but that he now "probably" supports expanding Medicaid in the state. The Kansas Hospital Association estimates that not expanding Medicaid has cost the state nearly $1.4 billion in federal funds (McLean, Salina Post, 9/6).
- Louisiana: K. Scott Wester, president and CEO of Baton Rouge-based Our Lady of the Lake Regional Medical Center, shares in Modern Healthcare several ways the hospital handled the state's historic flooding last month. "We had little time to prepare ourselves and our teams," he writes, adding that the 700-person strong clinical staff worked and slept in alternating 12-hour shifts, while the Coast Guard transported patients and care teams to and from flooded care centers. The hospital also set up a resource center for staff members who were affected by the floods (Wester, Modern Healthcare, 9/3).
- New York: State Attorney General Eric Schneiderman (D) on Tuesday announced an investigation into Mylan to determine whether the drugmaker wrongfully limited competition for its EpiPen. Schneiderman said a preliminary review conducted by his office found the company "may have inserted potentially anticompetitive terms into its EpiPen sales contracts with numerous local school systems." In a statement, Mylan acknowledged that it previously had included a "limited purchase restriction" in contracts with schools that intended to buy EpiPens beyond the no-cost supply they had been allotted, but said "such restriction no longer remains" (Hensch, The Hill, 9/6; Larson/Hopkins, Bloomberg, 9/6; Hufford, Wall Street Journal, 9/6).
Next in the Daily Briefing
Here's the cancer 'moonshot' panel's 10-point plan to fight cancer